There's a lot of tips and tricks to get the best 3D print possible, and one of the most useful you may not have heard of are ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to ...

Company announcement No. 21 / 2026Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and ...

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...